Project Grant R01AI179917
Award Date
7/23/24
Completion Date
5/31/29
Dollars Obligated
$1.4M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) in the amount of $609,924 will support research at the University of Rochester to investigate the mechanisms used by the pathogen Vibrio cholerae, which causes the severe diarrheal disease cholera, to coordinate virulence and physiological traits necessary for its dual aquatic and human pathogenic lifestyles. The research aims to identify and...
This federal Project Grant award of $779,235, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the molecular mechanisms and consequences of biofilm formation in Vibrio cholerae, the bacterium that causes cholera. The primary awardee, the University of California, Santa Cruz, will conduct research focused on: 1) determining how the bacterial second messenger...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $240,060 to the University of North Carolina at Chapel Hill to conduct research on Vibrio cholerae biofilms. The goal is to identify the cellular states and spatial arrangement of different V. cholerae cell populations within biofilms, as well as the cellular changes that occur during biofilm dispersal. This...
This $173,300 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports Phagepro, P.b.c. (doing business as Phagepro Inc.), a minority-owned, woman-owned small business, in planning for a Phase I/II clinical trial of their Prophylactic-VC (PVC) bacteriophage cocktail intervention to prevent the spread of cholera. The funding will be used to develop necessary clinical trial...
This federal Project Grant award of $708,202, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research to identify targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The award to Brown University will: 1) conduct a case-control study in Kenya to identify infants and children with severe malaria and matched controls, 2)...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $690,500 to Boston University Medical Campus to investigate the mechanisms underlying poor immune responses to the booster dose of the RTS,S malaria vaccine in African children. The key objectives are to: 1) identify specific antibody responses and functions that are suboptimal after the booster dose; 2)...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $822,209 to Illinois State University to conduct research on the regulation of the Vibrio cholerae MSHA pilus and its role in host colonization and pathogenesis. The key objectives of this 3-year research project are to: 1) characterize the promoter regions of the MSHA operons and evaluate the regulation of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $242,250 to the University of Virginia to develop a vaccine against cryptosporidiosis. The goal is to create a multi-stage vaccine targeting both the extracellular and intracellular life stages of the Cryptosporidium parasite, which causes a common and deadly diarrheal disease, especially in young children in...
This $4,004,843 Cooperative Agreement award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), aims to advance the understanding of systemic and mucosal immunity to enteric bacterial pathogens like Salmonella and Shigella in children and adults. The award supports research projects that will use human-based models and specimens from clinical studies to examine the immunological...
This $516,175 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the impact of pre-existing humoral immunity on hepatocyte death and its implications for malaria vaccine development. The grant, awarded to Seattle Children's Hospital's research institute, will fund a 2-year project exploring how non-neutralizing antibodies may promote apoptosis in...